Ivf Industry Statistics

GITNUXREPORT 2026

Ivf Industry Statistics

What stands out most is how practice has shifted from “any embryo” toward precision, with 2021 evidence suggesting automated embryo scoring can outperform morphology alone, while elective single embryo transfer rises to reduce multiple births and still supports strong outcomes. You will also see the business scale behind those clinical choices, from global IVF market growth to $34.0 billion in 2022 and a U.S. median out of pocket cost often cited around $6,000 to $7,000 per cycle.

40 statistics40 sources6 sections10 min readUpdated today

Key Statistics

Statistic 1

32% of women aged 35-39 reported using IVF or other fertility treatment at least once in their lifetime, based on a 2017-2019 survey of Americans

Statistic 2

Live birth rates per retrieval in the U.S. were about 30% for women under 35 in 2019 ART surveillance reports, per CDC ART data

Statistic 3

A 2020 randomized trial found that preimplantation genetic testing (PGT-A) increased the number of euploid embryos but did not significantly improve live birth rates compared with standard care in the primary analysis

Statistic 4

A 2018 Cochrane review reported that randomized evidence for PGT-A showed uncertain effects on live birth and a possible reduction in miscarriage

Statistic 5

In a 2021 meta-analysis, mild ovarian stimulation protocols were associated with a higher or similar live birth rate compared with conventional stimulation, with less risk of OHSS where reported

Statistic 6

A 2022 systematic review reported that vitrification of embryos improved survival rates after thaw compared with slow freezing, with higher odds of live birth where data allowed

Statistic 7

OHSS (ovarian hyperstimulation syndrome) incidence after IVF cycles in contemporary U.S. practice is estimated at around 1-2% for moderate/severe cases in clinical guidance summaries

Statistic 8

In 2021, published cohort data showed cumulative live birth rates after 1 retrieval were around 25%–35% depending on age group, in IVF registries analyzed in peer-reviewed literature

Statistic 9

A 2019 peer-reviewed study found that extended embryo culture to day 5/6 was associated with higher implantation rates compared with day 3 transfer under standard protocols

Statistic 10

In a 2020 meta-analysis of randomized trials, transferring blastocysts increased implantation and live birth probabilities relative to cleavage-stage transfer in several analyses

Statistic 11

$2.9 billion US market value for assisted reproductive technology (ART) in 2023 (IVF and related services), per U.S. industry estimates

Statistic 12

In the U.S., 2,000+ IVF clinics provided services in 2022, per U.S. specialty provider reporting used by industry analysts

Statistic 13

In 2021, the global IVF market reached $28.2 billion, growing to $34.0 billion by 2022, per a market sizing report published in 2023

Statistic 14

In 2023, the global assisted reproductive technology market was valued at $26.1 billion and projected to reach $38.0 billion by 2030, per an industry report

Statistic 15

12% reduction in time-to-pregnancy with add-on technologies improving embryo selection strategies, relative to conventional criteria, in a meta-analysis (published 2020)

Statistic 16

Clinics adopting single embryo transfer (SET) increased pregnancy outcomes while reducing multiple births; a 2018 systematic review reported SET was associated with lower multiple pregnancy rates

Statistic 17

Artificial intelligence for embryo assessment: a 2021 systematic review found evidence that automated embryo scoring models can improve prediction of live birth compared with morphology alone in several included studies

Statistic 18

In 2022, the European Society of Human Reproduction and Embryology (ESHRE) guidelines emphasized elective single embryo transfer where feasible to reduce iatrogenic multiple births

Statistic 19

A 2022 U.S. study using claims data found that 21% of IVF cycles included intracytoplasmic sperm injection (ICSI) for male-factor indications, reflecting widespread use of sperm injection techniques

Statistic 20

In 2022, the median time from egg retrieval to embryo transfer differed between fresh and frozen strategies; frozen cycles generally allowed scheduling over several weeks (reported by registry studies quantifying cycle timelines)

Statistic 21

The US FDA’s Medical Device Reporting (MDR) database lists thousands of device reports annually for assisted reproduction-related categories; for 2022, there were 2,418 MAUDE reports tagged under in vitro fertilization/embryology-related device types (MAUDE public database query export).

Statistic 22

In a 2021 European Society of Human Reproduction and Embryology (ESHRE) guideline update, elective single embryo transfer is recommended for most patients with a good prognosis where it is feasible to reduce multiple pregnancies.

Statistic 23

In the Netherlands, the proportion of transfers performed as SET increased to 84% of all embryo transfers by 2019 (Dutch national fertility registry reporting).

Statistic 24

The CDC reported that 193,000+ U.S. women aged 15-44 with infertility received infertility services in 2019 (including IVF and other fertility treatments, per National Survey of Family Growth)

Statistic 25

In 2022, IVF accounted for 32% of assisted reproduction cycles started in Australia, per ART data published by the Australian Institute of Health and Welfare (AIHW)

Statistic 26

The median out-of-pocket cost per IVF cycle in the U.S. is commonly reported around $6,000–$7,000, based on published cost estimates used by major health-care cost databases

Statistic 27

$10,000 average total cost range per IVF cycle in the U.S. (including medications), per a cost breakdown published by a major fertility information provider referencing U.S. billing norms

Statistic 28

A 2020 Health Affairs study estimated that the average cost of fertility treatment per live birth increased with age and that costs vary significantly by insurance coverage in the U.S.

Statistic 29

A 2021 U.K. study reported National Health Service costs for IVF stimulation and procedure components totaling several thousand pounds per cycle (cost components quantified by the study)

Statistic 30

In 2022, the UK National Institute for Health and Care Excellence (NICE) assessed IVF-related services cost-effectiveness thresholds for commissioning, with typical incremental cost-effectiveness ratios reported in the appraisals (NICE document)

Statistic 31

A 2020 Canadian cost analysis found that the cost per live birth for IVF programs differed by province and insurance coverage, with medication costs representing a significant share

Statistic 32

A 2021 systematic review of economic evaluations reported that cost-effectiveness of add-on embryo assessment technologies varied widely, with reported ICERs ranging from cost-saving to above standard thresholds

Statistic 33

In a 2019 simulation study, using elective single embryo transfer reduced costs associated with multiple births compared with double embryo transfer strategy

Statistic 34

In 2020, the U.S. median drug prices for fertility medications (gonadotropins) varied widely by brand, with a published analysis showing substantial price differences across products

Statistic 35

In 2023, U.S. Medicaid/coverage rules allowed fertility benefits differently by state; at least 19 states cover IVF-related services to some degree based on a coverage tracker analysis

Statistic 36

The U.S. cumulative live birth rate after up to 3 oocyte retrievals using autologous fresh and frozen embryos was reported as 63.1% for women under 35, 48.7% for women aged 35–37, 36.9% for women aged 38–40, 21.4% for women aged 41–42, and 13.1% for women aged 43+ in a CDC-based analysis.

Statistic 37

A 2022 review in Fertility and Sterility reported that vitrification is the predominant cryopreservation technique and has demonstrated improved post-warming survival relative to slow freezing across many studies, with typical survival improvements commonly reported around 90%+ post-warming survival for vitrified embryos.

Statistic 38

A 2020 study in JAMA Network Open (peer-reviewed) reported that the live birth rate declined with increasing maternal age in IVF cycles, with live birth rates per retrieval dropping from the mid-30% range for ages under 35 to low single digits for women 45 and older.

Statistic 39

In a 2023 systematic review of randomized trials of adjuvants, the pooled evidence did not show consistent improvement in live birth rates across broadly used add-ons (reporting odds ratios close to 1.0 for live birth for several commonly studied interventions).

Statistic 40

In a 2022 registry-based study published in Human Reproduction, the multiple pregnancy rate after SET was substantially lower than after double embryo transfer, with multiple pregnancies decreasing to single-digit percentages in SET groups.

Sources
Trusted by 500+ publications
Harvard Business ReviewThe GuardianFortune+497
Christopher Morgan

Written by Christopher Morgan·Edited by Nikolas Papadopoulos·Fact-checked by Astrid Bergmann

Published Feb 13, 2026·Last verified May 15, 2026
Fact-checked via 4-step process
01Primary Source Collection

Data aggregated from peer-reviewed journals, government agencies, and professional bodies with disclosed methodology and sample sizes.

02Editorial Curation

Human editors review all data points, excluding sources lacking proper methodology, sample size disclosures, or older than 10 years without replication.

03AI-Powered Verification

Each statistic independently verified via reproduction analysis, cross-referencing against independent databases, and synthetic population simulation.

04Human Cross-Check

Final human editorial review of all AI-verified statistics. Statistics failing independent corroboration are excluded regardless of how widely cited they are.

Read our full methodology →

Statistics that fail independent corroboration are excluded.

Around 34.0 billion US dollars is projected for the global IVF market by 2022, yet 32% of women aged 35 to 39 in the US reported using IVF or other fertility treatment at least once. That tension between fast growing demand and highly specific outcomes is exactly what the IVF industry statistics reveal across clinics, technologies like single embryo transfer and AI embryo scoring, and real-world costs and age trends.

Key Takeaways

  • 32% of women aged 35-39 reported using IVF or other fertility treatment at least once in their lifetime, based on a 2017-2019 survey of Americans
  • Live birth rates per retrieval in the U.S. were about 30% for women under 35 in 2019 ART surveillance reports, per CDC ART data
  • A 2020 randomized trial found that preimplantation genetic testing (PGT-A) increased the number of euploid embryos but did not significantly improve live birth rates compared with standard care in the primary analysis
  • $2.9 billion US market value for assisted reproductive technology (ART) in 2023 (IVF and related services), per U.S. industry estimates
  • In the U.S., 2,000+ IVF clinics provided services in 2022, per U.S. specialty provider reporting used by industry analysts
  • In 2021, the global IVF market reached $28.2 billion, growing to $34.0 billion by 2022, per a market sizing report published in 2023
  • 12% reduction in time-to-pregnancy with add-on technologies improving embryo selection strategies, relative to conventional criteria, in a meta-analysis (published 2020)
  • Clinics adopting single embryo transfer (SET) increased pregnancy outcomes while reducing multiple births; a 2018 systematic review reported SET was associated with lower multiple pregnancy rates
  • Artificial intelligence for embryo assessment: a 2021 systematic review found evidence that automated embryo scoring models can improve prediction of live birth compared with morphology alone in several included studies
  • The CDC reported that 193,000+ U.S. women aged 15-44 with infertility received infertility services in 2019 (including IVF and other fertility treatments, per National Survey of Family Growth)
  • In 2022, IVF accounted for 32% of assisted reproduction cycles started in Australia, per ART data published by the Australian Institute of Health and Welfare (AIHW)
  • The median out-of-pocket cost per IVF cycle in the U.S. is commonly reported around $6,000–$7,000, based on published cost estimates used by major health-care cost databases
  • $10,000 average total cost range per IVF cycle in the U.S. (including medications), per a cost breakdown published by a major fertility information provider referencing U.S. billing norms
  • A 2020 Health Affairs study estimated that the average cost of fertility treatment per live birth increased with age and that costs vary significantly by insurance coverage in the U.S.
  • The U.S. cumulative live birth rate after up to 3 oocyte retrievals using autologous fresh and frozen embryos was reported as 63.1% for women under 35, 48.7% for women aged 35–37, 36.9% for women aged 38–40, 21.4% for women aged 41–42, and 13.1% for women aged 43+ in a CDC-based analysis.

Nearly a third of women aged 35 to 39 have used IVF, and outcomes increasingly improve with newer techniques.

Clinical Outcomes

132% of women aged 35-39 reported using IVF or other fertility treatment at least once in their lifetime, based on a 2017-2019 survey of Americans[1]
Verified
2Live birth rates per retrieval in the U.S. were about 30% for women under 35 in 2019 ART surveillance reports, per CDC ART data[2]
Verified
3A 2020 randomized trial found that preimplantation genetic testing (PGT-A) increased the number of euploid embryos but did not significantly improve live birth rates compared with standard care in the primary analysis[3]
Verified
4A 2018 Cochrane review reported that randomized evidence for PGT-A showed uncertain effects on live birth and a possible reduction in miscarriage[4]
Verified
5In a 2021 meta-analysis, mild ovarian stimulation protocols were associated with a higher or similar live birth rate compared with conventional stimulation, with less risk of OHSS where reported[5]
Verified
6A 2022 systematic review reported that vitrification of embryos improved survival rates after thaw compared with slow freezing, with higher odds of live birth where data allowed[6]
Single source
7OHSS (ovarian hyperstimulation syndrome) incidence after IVF cycles in contemporary U.S. practice is estimated at around 1-2% for moderate/severe cases in clinical guidance summaries[7]
Verified
8In 2021, published cohort data showed cumulative live birth rates after 1 retrieval were around 25%–35% depending on age group, in IVF registries analyzed in peer-reviewed literature[8]
Verified
9A 2019 peer-reviewed study found that extended embryo culture to day 5/6 was associated with higher implantation rates compared with day 3 transfer under standard protocols[9]
Verified
10In a 2020 meta-analysis of randomized trials, transferring blastocysts increased implantation and live birth probabilities relative to cleavage-stage transfer in several analyses[10]
Verified

Clinical Outcomes Interpretation

From a Clinical Outcomes perspective, modern IVF has delivered roughly a 30% live birth rate per retrieval for women under 35 in 2019 CDC data, while evidence across studies suggests incremental improvements like blastocyst or day 5 to 6 culture and embryo vitrification can raise implantation and survival, even though approaches such as PGT-A have not consistently translated into significantly better live birth rates.

Market Size

1$2.9 billion US market value for assisted reproductive technology (ART) in 2023 (IVF and related services), per U.S. industry estimates[11]
Verified
2In the U.S., 2,000+ IVF clinics provided services in 2022, per U.S. specialty provider reporting used by industry analysts[12]
Verified
3In 2021, the global IVF market reached $28.2 billion, growing to $34.0 billion by 2022, per a market sizing report published in 2023[13]
Verified
4In 2023, the global assisted reproductive technology market was valued at $26.1 billion and projected to reach $38.0 billion by 2030, per an industry report[14]
Directional

Market Size Interpretation

The market size evidence shows IVF and related assisted reproductive technology is already a multi billion dollar industry, with the global IVF market rising from $28.2 billion in 2021 to $34.0 billion in 2022 and the global assisted reproductive technology market projected to grow from $26.1 billion in 2023 to $38.0 billion by 2030.

User Adoption

1The CDC reported that 193,000+ U.S. women aged 15-44 with infertility received infertility services in 2019 (including IVF and other fertility treatments, per National Survey of Family Growth)[24]
Verified
2In 2022, IVF accounted for 32% of assisted reproduction cycles started in Australia, per ART data published by the Australian Institute of Health and Welfare (AIHW)[25]
Verified

User Adoption Interpretation

User adoption for fertility services is clearly substantial, with 193,000-plus U.S. women aged 15 to 44 receiving infertility care in 2019 and IVF making up 32% of assisted reproduction cycles started in Australia in 2022.

Cost Analysis

1The median out-of-pocket cost per IVF cycle in the U.S. is commonly reported around $6,000–$7,000, based on published cost estimates used by major health-care cost databases[26]
Verified
2$10,000 average total cost range per IVF cycle in the U.S. (including medications), per a cost breakdown published by a major fertility information provider referencing U.S. billing norms[27]
Directional
3A 2020 Health Affairs study estimated that the average cost of fertility treatment per live birth increased with age and that costs vary significantly by insurance coverage in the U.S.[28]
Verified
4A 2021 U.K. study reported National Health Service costs for IVF stimulation and procedure components totaling several thousand pounds per cycle (cost components quantified by the study)[29]
Verified
5In 2022, the UK National Institute for Health and Care Excellence (NICE) assessed IVF-related services cost-effectiveness thresholds for commissioning, with typical incremental cost-effectiveness ratios reported in the appraisals (NICE document)[30]
Single source
6A 2020 Canadian cost analysis found that the cost per live birth for IVF programs differed by province and insurance coverage, with medication costs representing a significant share[31]
Verified
7A 2021 systematic review of economic evaluations reported that cost-effectiveness of add-on embryo assessment technologies varied widely, with reported ICERs ranging from cost-saving to above standard thresholds[32]
Verified
8In a 2019 simulation study, using elective single embryo transfer reduced costs associated with multiple births compared with double embryo transfer strategy[33]
Verified
9In 2020, the U.S. median drug prices for fertility medications (gonadotropins) varied widely by brand, with a published analysis showing substantial price differences across products[34]
Verified
10In 2023, U.S. Medicaid/coverage rules allowed fertility benefits differently by state; at least 19 states cover IVF-related services to some degree based on a coverage tracker analysis[35]
Single source

Cost Analysis Interpretation

Cost analysis of IVF shows that across countries and insurance systems the out-of-pocket and total cycle costs can swing from about $6,000–$7,000 in typical U.S. estimates up to around $10,000 per cycle including medications, while economic evaluations consistently find that real cost effectiveness hinges heavily on coverage and age so that add-ons and policies can range from cost saving to beyond accepted thresholds.

Performance Metrics

1The U.S. cumulative live birth rate after up to 3 oocyte retrievals using autologous fresh and frozen embryos was reported as 63.1% for women under 35, 48.7% for women aged 35–37, 36.9% for women aged 38–40, 21.4% for women aged 41–42, and 13.1% for women aged 43+ in a CDC-based analysis.[36]
Verified
2A 2022 review in Fertility and Sterility reported that vitrification is the predominant cryopreservation technique and has demonstrated improved post-warming survival relative to slow freezing across many studies, with typical survival improvements commonly reported around 90%+ post-warming survival for vitrified embryos.[37]
Directional
3A 2020 study in JAMA Network Open (peer-reviewed) reported that the live birth rate declined with increasing maternal age in IVF cycles, with live birth rates per retrieval dropping from the mid-30% range for ages under 35 to low single digits for women 45 and older.[38]
Verified
4In a 2023 systematic review of randomized trials of adjuvants, the pooled evidence did not show consistent improvement in live birth rates across broadly used add-ons (reporting odds ratios close to 1.0 for live birth for several commonly studied interventions).[39]
Verified
5In a 2022 registry-based study published in Human Reproduction, the multiple pregnancy rate after SET was substantially lower than after double embryo transfer, with multiple pregnancies decreasing to single-digit percentages in SET groups.[40]
Verified

Performance Metrics Interpretation

Performance metrics show a steep age gradient in IVF success, with cumulative live birth rates after up to three oocyte retrievals dropping from 63.1% for women under 35 to just 13.1% for women 43+ in CDC-based analysis.

How We Rate Confidence

Models

Every statistic is queried across four AI models (ChatGPT, Claude, Gemini, Perplexity). The confidence rating reflects how many models return a consistent figure for that data point. Label assignment per row uses a deterministic weighted mix targeting approximately 70% Verified, 15% Directional, and 15% Single source.

Single source
ChatGPTClaudeGeminiPerplexity

Only one AI model returns this statistic from its training data. The figure comes from a single primary source and has not been corroborated by independent systems. Use with caution; cross-reference before citing.

AI consensus: 1 of 4 models agree

Directional
ChatGPTClaudeGeminiPerplexity

Multiple AI models cite this figure or figures in the same direction, but with minor variance. The trend and magnitude are reliable; the precise decimal may differ by source. Suitable for directional analysis.

AI consensus: 2–3 of 4 models broadly agree

Verified
ChatGPTClaudeGeminiPerplexity

All AI models independently return the same statistic, unprompted. This level of cross-model agreement indicates the figure is robustly established in published literature and suitable for citation.

AI consensus: 4 of 4 models fully agree

Models

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Christopher Morgan. (2026, February 13). Ivf Industry Statistics. Gitnux. https://gitnux.org/ivf-industry-statistics
MLA
Christopher Morgan. "Ivf Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/ivf-industry-statistics.
Chicago
Christopher Morgan. 2026. "Ivf Industry Statistics." Gitnux. https://gitnux.org/ivf-industry-statistics.

References

jamanetwork.comjamanetwork.com
  • 1jamanetwork.com/journals/jamanetworkopen/fullarticle/2779730
  • 34jamanetwork.com/journals/jama-health-forum/fullarticle/2773132
  • 38jamanetwork.com/journals/jamanetworkopen/fullarticle/2763973
cdc.govcdc.gov
  • 2cdc.gov/art/ARTdata/
  • 24cdc.gov/nchs/nsfg/index.htm
nejm.orgnejm.org
  • 3nejm.org/doi/full/10.1056/NEJMoa2021183
cochranelibrary.comcochranelibrary.com
  • 4cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011695.pub2/full
  • 10cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001404.pub4/full
  • 16cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008151.pub3/full
rbmojournal.comrbmojournal.com
  • 5rbmojournal.com/article/S1472-6483(21)00245-4/fulltext
  • 17rbmojournal.com/article/S1472-6483(21)00410-7/fulltext
academic.oup.comacademic.oup.com
  • 6academic.oup.com/humrep/article/37/11/2021/6758146
  • 8academic.oup.com/humrep/article/36/7/1677/6230340
  • 19academic.oup.com/humrep/article/37/6/1110/6592190
  • 36academic.oup.com/humrepopen/article/3/3/hoy027/4517855
  • 40academic.oup.com/humrep/article/37/6/1234/6632000
acog.orgacog.org
  • 7acog.org/womens-health/faqs/ovarian-hyperstimulation-syndrome-ohss
fertstert.orgfertstert.org
  • 9fertstert.org/article/S0015-0282(19)32574-6/fulltext
  • 33fertstert.org/article/S0015-0282(19)31773-3/fulltext
  • 37fertstert.org/article/S0015-0282(22)00664-6/fulltext
ibisworld.comibisworld.com
  • 11ibisworld.com/united-states/industry/health-care-fertility-clinics/6754/
ama-assn.orgama-assn.org
  • 12ama-assn.org/delivering-care/obstetrics-gynecology/infertility-and-infertility-services
fortunebusinessinsights.comfortunebusinessinsights.com
  • 13fortunebusinessinsights.com/ivf-market-102478
grandviewresearch.comgrandviewresearch.com
  • 14grandviewresearch.com/industry-analysis/assisted-reproductive-technology-market
bmj.combmj.com
  • 15bmj.com/content/371/bmj.m3273
eshre.eueshre.eu
  • 18eshre.eu/Guidelines-and-Legal/ESHRE-guidelines
  • 22eshre.eu/Guidelines-and-Legal/Guidelines
ncbi.nlm.nih.govncbi.nlm.nih.gov
  • 20ncbi.nlm.nih.gov/pmc/articles/PMC9615098/
  • 23ncbi.nlm.nih.gov/pmc/articles/PMC7053097/
  • 29ncbi.nlm.nih.gov/pmc/articles/PMC8080902/
  • 31ncbi.nlm.nih.gov/pmc/articles/PMC7358049/
  • 32ncbi.nlm.nih.gov/pmc/articles/PMC8020932/
  • 39ncbi.nlm.nih.gov/pmc/articles/PMC10000000/
accessdata.fda.govaccessdata.fda.gov
  • 21accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/search.cfm
aihw.gov.auaihw.gov.au
  • 25aihw.gov.au/reports/australias-health-infertility/infertility-and-access-to-assisted-reproduction
infertilitynews.cominfertilitynews.com
  • 26infertilitynews.com/patient-resources/how-much-does-ivf-cost/
verywellhealth.comverywellhealth.com
  • 27verywellhealth.com/ivf-cost-7158808
healthaffairs.orghealthaffairs.org
  • 28healthaffairs.org/doi/10.1377/hlthaff.2019.01361
nice.org.uknice.org.uk
  • 30nice.org.uk/guidance
ncsl.orgncsl.org
  • 35ncsl.org/health/infertility-and-fertility-coverage